Literature DB >> 4686863

Staphylococcal osteomyelitis in children. Success with cephaloridine-cephalexin therapy.

S H Walker.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1973        PMID: 4686863     DOI: 10.1177/000992287301200213

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


× No keyword cloud information.
  7 in total

1.  Intravenous versus oral outpatient antibiotic therapy for pediatric acute osteomyelitis.

Authors:  Raymond W Liu; Hadeel Abaza; Priyesh Mehta; Jennifer Bauer; Daniel R Cooperman; Allison Gilmore
Journal:  Iowa Orthop J       Date:  2013

Review 2.  Acute hematogenous osteomyelitis in children: recognition and management.

Authors:  Andrew C Steer; Jonathan R Carapetis
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

3.  Sequential antibiotic therapy: Effective cost management and patient care.

Authors:  L A Mandell; M G Bergeron; M J Gribble; P J Jewesson; D E Low; T J Marrie; L E Nicolle
Journal:  Can J Infect Dis       Date:  1995-11

4.  Prolonged intravenous therapy versus early transition to oral antimicrobial therapy for acute osteomyelitis in children.

Authors:  Theoklis Zaoutis; A Russell Localio; Kateri Leckerman; Stephanie Saddlemire; David Bertoch; Ron Keren
Journal:  Pediatrics       Date:  2009-02       Impact factor: 7.124

5.  Acute haematogenous osteitis.

Authors:  J R Anderson; J D Orr; D A Maclean; W G Scobie
Journal:  Arch Dis Child       Date:  1980-12       Impact factor: 3.791

Review 6.  Shorter courses of parenteral antibiotic therapy do not appear to influence response rates for children with acute hematogenous osteomyelitis: a systematic review.

Authors:  Nicole Le Saux; Andrew Howard; Nicholas J Barrowman; Isabelle Gaboury; Margaret Sampson; David Moher
Journal:  BMC Infect Dis       Date:  2002-08-14       Impact factor: 3.090

7.  Cost-effective antibiotic prescribing.

Authors:  R Gleckman; N M Gantz
Journal:  Pharmacotherapy       Date:  1983 Jul-Aug       Impact factor: 4.705

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.